secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001437749-23-027674
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals appoints Moss Adams as new auditor after Armanino's exit
-------------------------------------------------------------------------------

- Audit Committee appointed Moss Adams LLP as independent accountant for fiscal year ending Dec 31, 2023 on Oct 4, 2023.
- Armanino LLP declines reappointment due to transition away from public company audits; notified company on July 18, 2023.
- Armanino's audit reports for 2021 and 2022 contained no adverse opinions; 2022 report included a going concern paragraph.
- No disagreements or reportable events occurred during Armanino's tenure through Oct 4, 2023.
- Armanino remains engaged to complete review of Q3 2023 unaudited financial statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923027674/0001437749-23-027674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923027674/rvph20231002_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-027674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer